The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I trial of ALT-801, a first-in-class T-cell receptor (TCR)-interleukin (IL)-2 fusion molecule, plus gemcitabine (G) for Bacillus Calmette Guerin (BCG)-resistant non-muscle-invasive bladder cancer (NMIBC).
 
Guru Sonpavde
Consulting or Advisory Role - Bayer; Genentech; Merck; Novartis; Pfizer; Sanofi
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Onyx (Inst)
 
Charles Joel Rosser
No Relationships to Disclose
 
Chong-xian Pan
Stock and Other Ownership Interests - Accelerated Medical Diagnostics; LP Therapeutics
Consulting or Advisory Role - Novartis
Research Funding - Abbott Diagnostics; Altor BioScience; Novartis
 
Rahul Atul Parikh
Stock and Other Ownership Interests - Gilead Sciences (I)
 
Jeffrey Nix
No Relationships to Disclose
 
Jeffrey R. Gingrich
No Relationships to Disclose
 
Liza Hernandez
Employment - Altor BioScience
 
Bee-Yau Huang
Employment - Altor BioScience
 
Hing C. Wong
Employment - Altor BioScience
Leadership - Altor BioScience